Jobs
-
The Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting regarding Breo Ellipta originally scheduled for March 7, 2013 has been rescheduled for April 17, 2013, from 8 am to 5 pm. The meeting was rescheduled due to… Read more . . .
-
Inhalation experts from the Woolcock Institute of Medical Research and the University of Sydney have launched a new company called Pulmatix to provide analytical services ranging from evaluation of APIs and formulations in respiratory cells… Read more . . .
-
According to Melbourn Scientific the company has recently been awarded a Manufacturer’s/Importer’s Authorization (MIA), which allows it to act as a testing and release site for the EU. Melbourn is among the largest suppliers of… Read more . . .
-
According to AstraZeneca, data from the PATHOS real world study show fewer exacerbations and fewer hospitalizations for COPD patients treated with the Symbicort Turbuhaler than for those treated with Seretide (Advair). The study was published… Read more . . .
-
Acorda Therapeutics presented data from a Phase 1 study of its diazepam nasal spray at the American Academy of Neurology Annual Meeting this week showing that the plasma bioavailability of a 20 mg dose of… Read more . . .
-
Savara Pharmaceuticals has received additional funding for Phase 2 development of its AeroVanc vancomycin inhalation powder for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in cystic fibrosis patients. The company brought its Series B… Read more . . .
-
Upsher Smith presented positive Phase 1 data for its USL261 intranasal midazolam at the American Academy of Neurology (AAN) Meeting this week. The company launched a website to recruit patients for a Phase 3 study… Read more . . .
-
According to Pharmaxis, the FDA has issued a complete response letter regarding its Bronchitol inhaled mannitol for the treatment of cystic fibrosis. The company says that the FDA requested another clinical trial. The Pharmaxis press… Read more . . .
-
According to Mylan, its subsidiary Mylan Specialty L.P. has received FDA approval for its Abbreviated New Drug Application (ANDA) for levalbuterol inhalation solution, a generic version of Sunovion’s Xopenex inhalation solution. The product is used… Read more . . .
-
Pearl Therapeutics was awarded the 2013 Drug Delivery Partnerships (DDP) Innovation Award for its co-suspension formulation technology, according to the company. The company is developing several metered dose inhalation products using the technology. President and… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland